These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26783595)

  • 1. [Spironolactone is the best option in "resistant" hypertension].
    Overbeck P
    MMW Fortschr Med; 2015 Sep; 157(16):9. PubMed ID: 26783595
    [No Abstract]   [Full Text] [Related]  

  • 2. [Resistant hypertension: often the therapy is to blame].
    Holzgreve H
    MMW Fortschr Med; 2016 Mar; 158(6):44. PubMed ID: 27084156
    [No Abstract]   [Full Text] [Related]  

  • 3. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.
    Oliveras A; Armario P; Clarà A; Sans-Atxer L; Vázquez S; Pascual J; De la Sierra A
    J Hypertens; 2016 Sep; 34(9):1863-71. PubMed ID: 27327441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aldosterone antagonists--first choice in resistant hypertension].
    Holzgreve H
    MMW Fortschr Med; 2016 Apr; 158(7):65-6. PubMed ID: 27071591
    [No Abstract]   [Full Text] [Related]  

  • 5. [Resistant hypertension].
    Bendersky M
    Rev Fac Cien Med Univ Nac Cordoba; 2012; 69(3):156-9. PubMed ID: 23286578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study.
    Rosa J; Widimský P; Waldauf P; Zelinka T; Petrák O; Táborský M; Branny M; Toušek P; Čurila K; Lambert L; Bednář F; Holaj R; Štrauch B; Václavík J; Kociánová E; Nykl I; Jiravský O; Rappová G; Indra T; Krátká Z; Widimský J
    J Hypertens; 2017 May; 35(5):1093-1099. PubMed ID: 28118281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation and pharmacologic approach to patients with resistant hypertension.
    Adams M; Bellone JM; Wright BM; Rutecki GW
    Postgrad Med; 2012 Jan; 124(1):74-82. PubMed ID: 22314117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and management of resistant hypertension: state of the art.
    Wei FF; Zhang ZY; Huang QF; Staessen JA
    Nat Rev Nephrol; 2018 Jul; 14(7):428-441. PubMed ID: 29700488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spironolactone in resistant hypertension.
    Feely J; Mahmud A
    Hypertension; 2007 Sep; 50(3):e57; author reply e58. PubMed ID: 17606857
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent onset severe hypertension requiring multiple antihypertensive medications.
    Diamond JA
    Am J Hypertens; 2001 Oct; 14(10):1073. PubMed ID: 11710788
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension.
    Schneider A; Schwab J; Karg MV; Kalizki T; Reinold A; Schneider MP; Schmieder RE; Schmidt BM
    J Hypertens; 2017 May; 35(5):1086-1092. PubMed ID: 28118280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe and refractory hypertension in a young woman.
    Cuadra RH; White WB
    J Am Soc Hypertens; 2016 Jun; 10(6):506-9. PubMed ID: 27160032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone: no longer for hypertension.
    Drug Ther Bull; 1988 Oct; 26(22):88. PubMed ID: 3181009
    [No Abstract]   [Full Text] [Related]  

  • 14. Spiroprop (spironolactone + propranolol) for hypertension.
    Drug Ther Bull; 1985 Apr; 23(8):31-2. PubMed ID: 3996214
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory versus resistant hypertension.
    Siddiqui M; Calhoun DA
    Curr Opin Nephrol Hypertens; 2017 Jan; 26(1):14-19. PubMed ID: 27798457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistant hypertension. What is the best approach?
    Barrios V; Escobar C
    Rev Esp Cardiol; 2009 Jun; 62(6):711-2; author reply 712. PubMed ID: 19480775
    [No Abstract]   [Full Text] [Related]  

  • 18. Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials.
    Liu L; Xu B; Ju Y
    Clin Exp Hypertens; 2017; 39(3):257-263. PubMed ID: 28448185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone for the treatment of isolated systolic hypertension.
    Yarows SA
    Am J Hypertens; 2004 Mar; 17(3):284. PubMed ID: 15001208
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug adherence monitoring in clinical trials: a necessity for a correct assessment of the efficacy and safety of antihypertensive therapies.
    Burnier M; Wuerzner G
    J Hypertens; 2015 Dec; 33(12):2395-8. PubMed ID: 26485464
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.